These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33733904)

  • 21. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants.
    Meijers JCM; Bakhtiari K; Zwiers A; Peters SLM
    Thromb Res; 2023 Jul; 227():17-24. PubMed ID: 37207560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study.
    Doeppner TR; Olbricht L; Maxhuni T; Alhaj Omar O; Sachs UJ; Juenemann MB; Huttner HB; Gerner ST
    Front Neurol; 2023; 14():1330421. PubMed ID: 38162451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay.
    Artang R; Anderson M; Riley P; Nielsen JD
    Res Pract Thromb Haemost; 2017 Oct; 1(2):194-201. PubMed ID: 30046690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay.
    Kopatz WF; Brinkman HJM; Meijers JCM
    Thromb Res; 2018 Oct; 170():97-101. PubMed ID: 30149286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants.
    Metze M; Klöter T; Stöbe S; Rechenberger B; Siegemund R; Siegemund T; Laufs U; Petros S; Pfrepper C
    Int J Lab Hematol; 2021 Dec; 43(6):1539-1548. PubMed ID: 34097808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on laboratory assessment for direct oral anticoagulants (DOACs).
    Gosselin RC; Adcock DM; Douxfils J
    Int J Lab Hematol; 2019 May; 41 Suppl 1():33-39. PubMed ID: 31069969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
    Brückner L; Beyer-Westendorf J; Tiebel O; Pietsch J
    J Thromb Thrombolysis; 2022 May; 53(4):777-787. PubMed ID: 34762222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
    Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
    Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
    Vercruyssen J; Meeus P; Bailleul E
    Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.
    Harenberg J; Gosselin RC; Cuker A; Becattini C; Pabinger I; Poli S; Weitz J; Ageno W; Bauersachs R; Celap I; Choi P; Douketis J; Douxfils J; Elalamy I; Falanga A; Fareed J; Favaloro EJ; Gerotziafas G; Herkner H; Hetjens S; Heubner L; Klamroth R; Langer F; Lip GYH; Grory BM; Margetić S; Merrelaar A; Pikta M; Renne T; Schulman S; Schwameis M; Strbian D; Tafur A; Vassart J; Violi F; Walenga J; Weiss C
    Thromb Haemost; 2024 Aug; 124(8):770-777. PubMed ID: 38316416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
    Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
    Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.